Suppr超能文献

随机、双盲、安慰剂对照研究多菌种益生菌混合物治疗非酒精性脂肪性肝病。

Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease.

机构信息

Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea.

Department of Internal Medicine, Hanyang University School of Medicine, Hanyang University Medical Center, Seoul, Korea.

出版信息

Sci Rep. 2019 Apr 5;9(1):5688. doi: 10.1038/s41598-019-42059-3.

Abstract

The intestinal microbiota is closely associated with the development of obesity and nonalcoholic fatty liver disease (NAFLD). This study investigated the effects of probiotic treatment on visceral fat area (VFA) and intrahepatic fat (IHF) fraction in NAFLD. Sixty-eight obese NAFLD patients (>5% proton density fat fraction [PDFF] on magnetic resonance imaging [MRI]) were randomized to probiotic and placebo groups for 12 weeks. The probiotic mixture included 6 bacterial species. VFA and IHF were measured using the MRI-PDFF technique. Body weight and total body fat were reduced in the probiotic group but not in the placebo group. The mean IHF fraction was reduced after 12 weeks of treatment in the probiotic group compared to that at baseline (from 16.3 ± 15.0% to 14.1 ± 7.7%, p = 0.032) but was not reduced in the placebo group. The decrease in IHF (mean difference: -2.61%, p = 0.012) was also greater in the probiotic group than in the placebo group. Reduction of triglyceride was greater in the probiotic treatment group than in the placebo group (mean difference: -34.0 mg/dl, p = 0.0033). However, the changes in IHF percentage and triglyceride levels were not different between placebo and control groups after adjusting for changes in body weight. Treatment with probiotics for 12 weeks resulted in significant reduction in IHF and body weight in obese NAFLD patients.

摘要

肠道微生物群与肥胖和非酒精性脂肪性肝病(NAFLD)的发展密切相关。本研究探讨了益生菌治疗对 NAFLD 患者内脏脂肪面积(VFA)和肝内脂肪(IHF)分数的影响。68 名肥胖的 NAFLD 患者(磁共振成像 [MRI]质子密度脂肪分数 [PDFF]>5%)按益生菌和安慰剂组随机分为 12 周。益生菌混合物包含 6 种细菌。使用 MRI-PDFF 技术测量 VFA 和 IHF。益生菌组体重和全身脂肪减少,但安慰剂组没有。与基线相比,益生菌组治疗 12 周后 IHF 分数降低(从 16.3±15.0%降至 14.1±7.7%,p=0.032),但安慰剂组没有降低。益生菌组与安慰剂组相比,IHF 的降低更为显著(平均差异:-2.61%,p=0.012)。益生菌治疗组的甘油三酯降低幅度也大于安慰剂组(平均差异:-34.0mg/dl,p=0.0033)。然而,调整体重变化后,安慰剂组和对照组之间 IHF 百分比和甘油三酯水平的变化没有差异。在肥胖的 NAFLD 患者中,用益生菌治疗 12 周可显著降低 IHF 和体重。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3a7/6450966/3ae33524c853/41598_2019_42059_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验